Cargando…

Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial

OBJECTIVE: Somapacitan is a reversible albumin-binding growth hormone (GH) derivative, developed for once-weekly administration. This study aimed to evaluate the safety of once-weekly somapacitan vs once-daily Norditropin(®). Local tolerability and treatment satisfaction were also assessed. DESIGN:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Johannsson, Gudmundur, Feldt-Rasmussen, Ulla, Håkonsson, Ida Holme, Biering, Henrik, Rodien, Patrice, Tahara, Shigeyuki, Toogood, Andrew, Rasmussen, Michael Højby, Karges, Wolfram, Mann, Alexander, Christiansen, Jens Sandahl, Hansen, Troels Krarup, Andersen, Marianne, Borresen, Sine, Borson-Chazot, Françoise, Kerlan, Véronique, Cariou, Bertrand, Verges, Bruno, Matsuno, Akira, Takano, Koji, Tagami, Tetsuya, Takahashi, Yutaka, Takahashi, Toshikazu, Yamamoto, Masahiro, Höybye, Charlotte, Erfurth, Eva-Marie, Drake, William, Higham, Claire, Murray, Robert, Brooke, Antonia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bioscientifica Ltd 2018
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5920019/ https://www.ncbi.nlm.nih.gov/pubmed/29500310 http://dx.doi.org/10.1530/EJE-17-1073

Ejemplares similares

Once-weekly Somapacitan is Effective and Well Tolerated in Adults with GH Deficiency: A Randomized Phase 3 Trial
por: Johannsson, Gudmundur, et al.
Publicado: (2020)

SAT-LB074 Efficacy and Safety of Once-weekly Somapacitan in Adult Growth Hormone Deficiency (AGHD) Confirmed in a 53‑week Real 1 Trial Extension
por: Johannsson, Gudmundur, et al.
Publicado: (2019)

Dose–exposure–IGF-I response of once-weekly somapacitan in adults with GH deficiency
por: Kildemoes, Rasmus Juul, et al.
Publicado: (2022)

Similar safety and efficacy in previously treated adults with growth hormone deficiency randomized to once‐weekly somapacitan or daily growth hormone
por: Otsuka, Fumio, et al.
Publicado: (2020)

Weekly somapacitan had no adverse effects on glucose metabolism in adults with growth hormone deficiency
por: Takahashi, Yutaka, et al.
Publicado: (2022)

MON-265 Once-Weekly Somapacitan in Japanese Adults with GH Deficiency Was Well Tolerated, with Similar Efficacy to Daily GH: A Randomized Trial
por: Otsuka, Fumio, et al.
Publicado: (2020)

Optimal Monitoring of Weekly IGF-I Levels During Growth Hormone Therapy With Once-Weekly Somapacitan
por: Juul Kildemoes, Rasmus, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Once-Weekly Somapacitan in Children and Adults: Supporting Dosing Rationales with a Model-Based Analysis of Three Phase I Trials
por: Juul, Rasmus Vestergaard, et al.
Publicado: (2018)

Weekly Somapacitan in GH Deficiency: 4-Year Efficacy, Safety, and Treatment/Disease Burden Results From REAL 3
por: Sävendahl, Lars, et al.
Publicado: (2023)

SAT-LB12 Once-Weekly Somapacitan vs Daily Growth Hormone in Growth Hormone Deficiency: 2-Year Safety Results From Real 3, a Randomized Phase 2 Trial
por: Savendahl, Lars S, et al.
Publicado: (2020)

Effective GH Replacement With Once-weekly Somapacitan vs Daily GH in Children with GHD: 3-year Results From REAL 3
por: Sävendahl, Lars, et al.
Publicado: (2021)

Once-Weekly Somapacitan vs Daily GH in Children With GH Deficiency: Results From a Randomized Phase 2 Trial
por: Sävendahl, Lars, et al.
Publicado: (2020)

SAT-091 First Report of Disease-Specific Patient-Reported Outcomes from a Randomized Phase 2 Trial of Once-Weekly Somapacitan vs Daily GH in Children with GHD
por: Brod, Meryl, et al.
Publicado: (2020)

THU174 Model-Based Analysis Of IGF-I Response, Dosing, And Monitoring For Once-Weekly Somapacitan In Children With GH Deficiency
por: Kildemoes, Rasmus Juul, et al.
Publicado: (2023)

Weekly Somapacitan is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial
por: Miller, Bradley S, et al.
Publicado: (2022)

Radioiodine treatment for non-toxic goitre
por: Feldt-Rasmussen, Ulla
Publicado: (2009)

Recent advances in understanding autoimmune thyroid disease: the tallest tree in the forest of polyautoimmunity
por: Bliddal, Sofie, et al.
Publicado: (2017)

SUN-247 Once-Weekly Somapacitan in Childhood Growth Hormone Deficiency: Efficacy and Safety Results of a Randomized, Open-Label, Controlled Phase 2 Trial (REAL 3)
por: Savendahl, Lars, et al.
Publicado: (2019)

RF26 | PMON334 Once-Weekly Somapacitan in Growth Hormone Deficiency: 4-Year Efficacy and Safety Results from REAL 3, a Randomised Controlled Phase 2 Trial
por: Savendahl, Lars, et al.
Publicado: (2022)

Introduction to European comments on “Medullary Thyroid Cancer: management guidelines of the American Thyroid Association”
por: Jarzab, Barbara, et al.
Publicado: (2013)

Results and summary of voting among the audience during presentation and discussion of Medullary Thyroid Carcinoma clinical guidelines prepared by American Thyroid Association
por: Feldt-Rasmussen, Ulla, et al.
Publicado: (2013)

Hypopituitarism in Traumatic Brain Injury—A Critical Note
por: Klose, Marianne, et al.
Publicado: (2015)

Long-term Safety of Growth Hormone in Adults With Growth Hormone Deficiency: Overview of 15 809 GH-Treated Patients
por: Johannsson, Gudmundur, et al.
Publicado: (2022)

RF14 | LBMON195 Once-weekly Somapacitan Is Effective And Well Tolerated In Children With GH Deficiency: A Randomized Phase 3 Trial
por: Miller, Bradley, et al.
Publicado: (2022)

Response to Letter to the Editor From Chatelain et al: “Weekly Somapacitan Is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial”
por: Miller, Bradley S, et al.
Publicado: (2023)

Graves’ Disease in the Young: Could We Change the Weather?
por: Rodien, Patrice
Publicado: (2021)

Positron Emission Tomography and Magnetic Resonance Imaging of the Brain in Fabry Disease: A Nationwide, Long-Time, Prospective Follow-Up
por: Korsholm, Kirsten, et al.
Publicado: (2015)

The Influence of Triclosan on the Thyroid Hormone System in Humans - A Systematic Review
por: Homburg, Mai, et al.
Publicado: (2022)

Levothyroxine Therapy in Elderly Patients With Hypothyroidism
por: Effraimidis, Grigoris, et al.
Publicado: (2021)

Effect of Kidney or Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Somapacitan: Two Open-Label, Parallel-Group Trials
por: Bentz Damholt, Birgitte, et al.
Publicado: (2021)

SAT-505 Non-Adherence to Levothyroxine Treatment, a Condition Not to Be Ignored nor Forgotten, Should Be Assessed by Thyroxine Absorption Test
por: Effraimidis, Grigorios, et al.
Publicado: (2020)

ODP350 Safety and Efficacy of Tesomet over 48 Weeks of Treatment: Results From a 24-Week Phase 2, Randomized, Double-Blind Study With 24 Week Open-Label Extension in Adults With Hypothalamic Obesity
por: Klose, Marianne, et al.
Publicado: (2022)

Model-Based Analysis of IGF-I Response, Dosing, and Monitoring for Once-Weekly Somapacitan in Children With GH Deficiency
por: Kildemoes, Rasmus J, et al.
Publicado: (2023)

Fabry disease, respiratory symptoms, and airway limitation – a systematic review
por: Svensson, Camilla Kara, et al.
Publicado: (2015)

Thyroid Autoimmunity and Function after Treatment with Biological Antirheumatic Agents in Rheumatoid Arthritis
por: Bliddal, Sofie, et al.
Publicado: (2017)

Insulin Independence in Newly Diagnosed Type 1 Diabetes Patient following Fenofibrate Treatment
por: Buschard, Karsten, et al.
Publicado: (2020)

Identification of human glucocorticoid response markers using integrated multi-omic analysis from a randomized crossover trial
por: Chantzichristos, Dimitrios, et al.
Publicado: (2021)

Semen quality in patients with pituitary disease and adult-onset hypogonadotropic hypogonadism
por: Andreassen, Mikkel, et al.
Publicado: (2018)

Less known aspects of central hypothyroidism: Part 2 – Congenital etiologies
por: Benvenga, Salvatore, et al.
Publicado: (2018)

Less known aspects of central hypothyroidism: Part 1 – Acquired etiologies
por: Benvenga, Salvatore, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_o58d955sbj8e46p4pu28ibcml4